CoChat

Revisiting Therapies for Atopic Dermatitis that Failed Clinical Trials

Agnihotri, Gaurav, Lio, Peter A. · 2020 · Clinical Drug Investigation

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Multiple pathways contribute to the pathogenesis of atopic dermatitis (AD), and various targeted topical, biologic, and oral systemic agents have subsequently been developed. This review examines the mechanism of action and study designs of agents that have failed trials for AD to identify lessons that may shed light on reasons for their failure. Clinicaltrials.gov was searched for completed, placebo-controlled phase II and III studies assessing agents for AD that did not meet the primary endpoint, specifically reduction of AD severity. PubMed was then searched for further data on the agents identified with known mechanism of actions. Only phase II trials met inclusion criteria. Analyses of the mechanisms of action, study design, and patient demographics of the failed clinical trials for the following agents are presented: apremilast and roflumilast (PDE-4 inhibitors), fevipiprant and temapiprant (CRTH2 inhibitors), and tezepelumab and ustekinumab (monoclonal antibodies). Agents that did not meet their trial endpoints for AD may still hold therapeutic value in certain subpopulation groups or other diseases. Validating phase II trials based off subgroup analyses from previous trials may be warranted as our understanding of the pathophysiology of AD continues to grow.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40261-020-00905-7

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, Paris M, Teng L, Wollenhaupt J. Consistent safety profile with up to 4 years of apremilast treatment: analysis of data from 1493 subjects with psoriatic arthritis in 3 large, phase III, long-term studies [abstract]. Arthritis Rheumatol. 2017;69:604.

Cited by

See all 15

Metadata

Authors
Agnihotri, G., & Lio, P. A.
Affiliations
  • University of Illinois Chicago (US)
  • Northwestern University (US)
Corresponding author
Lio, Peter A.
Venue
Clinical Drug Investigation
Published
2020-03-14
Volume
40
Issue
5
Pages
421-431
ISSN
  • 0114-2402 (ISSN-L)
  • 1173-2563
  • 1179-1918
OpenAlex
W3011685038
Cited by
15
References
47
Citations by year
2026: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 6 · 2020: 2
FWCI
0.50
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Clinical Drug Investigation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
Keywords
atopic dermatitis, clinical trial failure, drug development, apremilast, roflumilast, phosphodiesterase-4 inhibitors, fevipiprant, tezepelumab, ustekinumab, monoclonal antibodies, subgroup analysis, mechanism of action
MeSH terms
Clinical Trials as Topic, Dermatitis, Atopic, Dermatologic Agents, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.